Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis

• Published in: Drugs (New York, N.Y.) Vol. 84; no. 5; pp. 565 - 578
• Main Authors: Thomas, Sarah E., Barenbrug, Liana, Hannink, Gerjon, Seyger, Marieke M. B., de Jong, Elke M. G. J., van den Reek, Juul M. P. A.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.05.2024; Springer Nature B.V
• Subjects: Adverse events; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - pharmacology; Antibodies, Monoclonal, Humanized - therapeutic use; Automation; Biological effects; Biological products; Biopharmaceuticals; Body mass index; Clinical trials; Cohort analysis; Cytokines; Dermatologic Agents - adverse effects; Dermatologic Agents - pharmacology; Dermatologic Agents - therapeutic use; Electronic health records; Electronic medical records; Estimates; FDA approval; Humans; Inhibitors; Interleukin 17; Interleukin 23; Interleukin-17 - antagonists & inhibitors; Interleukin-23 - antagonists & inhibitors; Internal Medicine; Medicine; Medicine & Public Health; Meta-analysis; Monoclonal antibodies; Patients; Pharmacology/Toxicology; Pharmacotherapy; Pharmacy; Psoriasis; Psoriasis - drug therapy; Psoriatic arthritis; Skin diseases; Survival; Survival analysis; Systematic Review
• ISSN: 0012-6667; 1179-1950; 1179-1950
• DOI: 10.1007/s40265-024-02028-1

Background and Objective The most recently approved biologics for moderate-to-severe psoriasis are the interleukin (IL)-17 and IL-23 inhibitors. Drug survival is a frequently used outcome to assess drug performance in practice. An overview of the available drug survival studies regarding IL-17 and IL-23 inhibitors is lacking. Therefore, our objective was to assess the drug survival of IL-17 and IL-23 inhibitors for psoriasis. Methods A search of PubMed, Embase, Cochrane Library and Web of Science was conducted (last search 27 December, 2023). Inclusion criteria were (1) cohort study; (2) patients aged ≥ 18 years with plaque psoriasis; and (3) evaluation of drug survival of at least one of the IL-17 and IL-23 inhibitors. Exclusion criteria were: primary focus on patients with psoriatic arthritis, fewer than ten study subjects and another language than English. The Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guideline was followed. Survival probabilities at monthly intervals were extracted from Kaplan–Meier curves using a semi-automated tool. Data were pooled using a non-parametric random-effects model to retrieve distribution-free summary survival curves. Summary drug survival curves were constructed per biologic for different discontinuation reasons: overall, ineffectiveness and adverse events, and split for the effect modifier biologic naivety. Results were analysed separately for registry/electronic health record data and for pharmacy/claims data. Results A total of 69 studies aggregating drug survival outcomes of 48,704 patients on secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, and tildrakizumab were included. Summary drug survival estimates of registry/electronic health record studies for overall, ineffectiveness and adverse event related drug survival were high (all point estimates ≥ 0.8 at year 1) for included biologics, with highest estimates for guselkumab and risankizumab. All estimates for drug survival were higher in biologic naive than in experienced patients. Estimates of pharmacy/claims databases were substantially lower than estimates from the primary analyses based on registry/electronic health record data. Conclusions This meta-analysis showed that the investigated IL-17 and IL-23 inhibitors had high drug survival rates, with highest rates for guselkumab and risankizumab drug survival. We showed that effect modifiers such as biologic naivety, and the source of data used (registry/electronic health record data vs pharmacy/claims databases) is relevant when interpreting drug survival studies.